Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 18/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 0.72 |
| ▸ | MAOB | P27338 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21780064 | 1.00 | AOC3 (1.00) | AOC3MAOAMAOB | |
| SCHEMBL28582819 | 1.00 | AOC3 (1.00) | AOC3MAOAMAOB | |
| Hydrochloric Acid SCHEMBL21768039 | 0.99 | AOC3 (0.98) | AOC3MAOAMAOB | |
| Hydrochloric Acid SCHEMBL21768038 | 0.99 | AOC3 (0.98) | AOC3MAOAMAOB | |
| Hydrochloric Acid SCHEMBL22713764 | 0.99 | AOC3 (0.98) | AOC3MAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL21768138 | 0.93 | AOC3 (0.86) | AOC3MAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL21768137 | 0.93 | AOC3 (0.86) | AOC3MAOAMAOB | |
| SCHEMBL21040302 | 0.90 | AOC3 (0.81) | AOC3MAOAMAOB | |
| SCHEMBL24668519 | 0.87 | AOC3 (0.78) | AOC3MAOAMAOB | |
| SCHEMBL23068721 | 0.86 | AOC3 (0.75) | AOC3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-20200087248-A1 | Fluoroallylamine Derivative And Use Thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-03-19 | — | — | US | disclosed |
| EP-3617186-A1 | FLUOROALLYLAMINE DERIVATIVE AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087248-A1 | Fluoroallylamine Derivative And Use Thereof | VAPB, VAPA, SLC28A1 | AOC3 6/4885MAOA 25/4885MAOB 60/4885 |
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | VCAM1, VAPB, ICAM1 | AOC3 6/4885MAOA 13/4885MAOB 16/4885 |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | VCAM1, VAPB, ICAM1 | AOC3 6/4885MAOA 13/4885MAOB 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.